MoonLake Immunotherap Price Target Maintained With a $66.00/Share by Needham
MoonLake Analyst Ratings
MoonLake Immunotherapeutics: Promising Clinical Trials and Market Potential Drive Buy Rating
Stifel Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $77
Cantor Fitzgerald Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating
BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $81
Guggenheim Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $80
RBC Capital Initiates MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Announces Target Price $67
MoonLake Immunotherap Price Target Announced at $67.00/Share by RBC Capital
MoonLake Analyst Ratings
Correction: RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $67 Price Target
RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $17 Price Target
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $75
TD Cowen Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $100
Goldman Sachs Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $73
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $66 to $100
MoonLake Immunotherap Is Maintained at Buy by Needham
MoonLake Analyst Ratings
Needham Maintains Buy on MoonLake, Raises Price Target to $66